Literature DB >> 3803419

Pharmacokinetics of N-acetylcysteine in man.

L Borgström, B Kågedal, O Paulsen.   

Abstract

N-Acetylcysteine was given intravenously and as three fast dissolving and one slow-release formulation, on separate occasions, as a single dose of 600 mg to 10 fasting (5 men and 5 women) healthy volunteers. Blood and urine were sampled for the following 12 h. Renal clearance constituted around 30% of total body clearance, which was 0.21 l/h/kg. Volume of distribution was 0.33 l/kg, consistent with distribution mainly to extracellular water. The late elimination half-life was 2.27 h and the mean residence time 1.62 h. The slow-release tablet resulted in a flattened plasma concentration-time curve typical of slow release formulations, while the other three oral formulations were rapidly absorbed. The oral availability of N-acetylcysteine varied between 6 and 10%, with the slow-release tablet having the lowest and the fast dissolving tablet the highest availability.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3803419     DOI: 10.1007/bf00606662

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Acetylcysteine in the prevention of cyclophosphamide-induced cystitis in rats.

Authors:  J A Botta; L W Nelson; J H Weikel
Journal:  J Natl Cancer Inst       Date:  1973-09       Impact factor: 13.506

2.  A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine.

Authors:  C Myers; R Bonow; S Palmeri; J Jenkins; B Corden; G Locker; J Doroshow; S Epstein
Journal:  Semin Oncol       Date:  1983-03       Impact factor: 4.929

3.  Determination of non-protein-bound N-acetylcysteine in plasma by high-performance liquid chromatography.

Authors:  B Kågedal; M Källberg; J Mårtensson
Journal:  J Chromatogr       Date:  1984-11-09

4.  N-acetylcysteine: its bioavailability and interaction with ifosfamide metabolites.

Authors:  L R Morgan; M R Holdiness; L E Gillen
Journal:  Semin Oncol       Date:  1983-03       Impact factor: 4.929

5.  Determination of N-acetyl-L-cysteine in biological fluids.

Authors:  H Frank; D Thiel; K Langer
Journal:  J Chromatogr       Date:  1984-08-10

6.  Long-term oral acetylcysteine in chronic bronchitis. a double-blind controlled study.

Authors: 
Journal:  Eur J Respir Dis Suppl       Date:  1980

7.  Pharmacokinetics of oral acetylcysteine: absorption, binding and metabolism in patients with respiratory disorders.

Authors:  D Rodenstein; A DeCoster; A Gazzaniga
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

8.  Reversed-phase ion-pair high-performance liquid chromatography of mercaptoacetate and N-acetylcysteine after derivatization with N-(1-pyrene)maleimide and N-(7-dimethylamino-4-methyl-3-coumarinyl)maleimide.

Authors:  B Kågedal; M Källberg
Journal:  J Chromatogr       Date:  1982-05-14

9.  Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo.

Authors:  B H Lauterburg; G B Corcoran; J R Mitchell
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

10.  Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases.

Authors:  G Boman; U Bäcker; S Larsson; B Melander; L Wåhlander
Journal:  Eur J Respir Dis       Date:  1983-08
View more
  74 in total

Review 1.  Respiratory muscle function and free radicals: from cell to COPD.

Authors:  L M Heunks; P N Dekhuijzen
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

2.  Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease.

Authors:  Thomas D Nolin; Rosemary Ouseph; Jonathan Himmelfarb; M Elizabeth McMenamin; Richard A Ward
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

3.  Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine.

Authors:  B Olsson; M Johansson; J Gabrielsson; P Bolme
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise.

Authors:  Malcolm Brown; Andrew Bjorksten; Ivan Medved; Michael McKenna
Journal:  Eur J Clin Pharmacol       Date:  2004-11-20       Impact factor: 2.953

Review 5.  Contrast-induced acute kidney injury and diabetic nephropathy.

Authors:  Andrew D Calvin; Sanjay Misra; Axel Pflueger
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

6.  EJCP and clinical toxicology: the first 40 years.

Authors:  D N Bateman
Journal:  Eur J Clin Pharmacol       Date:  2007-11-16       Impact factor: 2.953

7.  Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels.

Authors:  Raghavendra S Navath; Yunus E Kurtoglu; Bing Wang; Sujatha Kannan; Robert Romero; Rangaramanujam M Kannan
Journal:  Bioconjug Chem       Date:  2008-12       Impact factor: 4.774

8.  N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication.

Authors:  Luís Eduardo S Fontes; Ana Luiza C Martimbianco; Carolina Zanin; Rachel Riera
Journal:  Cochrane Database Syst Rev       Date:  2019-02-12

9.  Preventing contrast-induced nephropathy in patients with baseline renal dysfunction undergoing coronary angiography.

Authors:  Po-Tsang Lee; Kang-Ju Chou; Hua-Chang Fang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-02

10.  N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients.

Authors:  Tariq Rehman; Jason Fought; Richard Solomon
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.